The Metabolomics Service shared resource (Metabolomics) of the Rutgers Cancer Institute of New Jersey (CINJ) is a Cancer Center managed shared resource whose purpose is to enable state-of-the-art analysis of cancer metabolism. The past decade has seen a surge of interest in tumor metabolism, driven by the recognition that oncogenes up-regulate metabolism and that certain metabolites can themselves cause cancer (?oncometabolites?). The discovery of the best-established oncometabolite, 2-hydroxyglutarate, involved a central contribution from Joshua Rabinowitz, Director of this Metabolomics shared resource. The shared resource?s mission is two-fold: 1) to continue to push the frontiers of tumor metabolism measurement, enabling additional such scientific discoveries that significantly impact cancer diagnosis and therapy and 2) to provide CINJ members with easy, cost-effective access to these capabilities, thereby enhancing productivity across the consortium. To this end, the shared resource provides access to basic metabolism measurement capabilities, like oxygen consumption, which involve instruments that are readily shared (e.g., Seahorse). It also provides more advanced services, such as large-scale quantitative metabolite measurement by LC-MS. In addition, it develops and collaboratively applies cutting-edge metabolism measurement capabilities that are unique or available in only a handful of institutions world-wide (e.g. quantitative analysis of tumor-host metabolic interplay in vivo using isotope tracers). Building from informal collaborations that started in 2011, the consortium cancer center, with support from CCSG Developmental Funds, established a CCSG-supported developing shared resource for Metabolomics. This shared resource involved substantial investments by both Rutgers and Princeton Universities, in the form of multiple instruments purchased by each university. This shared resource not only met the existing need for metabolic analysis, but also encouraged investigators, through a variety of programmatic platforms, to pursue cancer metabolism research. MSR, Page 1 of 1; DRAFT 1/18/18 8:28 AM !

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rbhs -Cancer Institute of New Jersey
New Brunswick
United States
Zip Code
Farber, Nicholas J; Radadia, Kushan D; Singer, Eric A (2018) Accuracy of Nodal Staging and Outcomes of Lymphadenectomy for Non-metastatic Renal Cell Carcinoma: An Analysis of the National Cancer Database. Bladder Cancer 4:S14-S15
Poillet-Perez, Laura; Xie, Xiaoqi; Zhan, Le et al. (2018) Autophagy maintains tumour growth through circulating arginine. Nature 563:569-573
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803

Showing the most recent 10 out of 775 publications